Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Adalimumab 13Etanercept 8Methotrexate 7Rituximab 6Abatacept 6tocilizumab 5golimumab 5tofacitinib 4olokizumab 4Certolizumab Pegol 4Tumor Necrosis Factor Inhibitors 3Infliximab 3Saline Solution 2Antirheumatic Agents 2upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1Sulfasalazine 1Sodium Chloride 1Radioimmunodetection 1RC-18 1Pharmaceutical Preparations 1Lysine Acetyltransferase 5 1Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Arthritis, Rheumatoid × ISIS104838 × Clear all
NCT00048321 2022-12-05

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Ionis Pharmaceuticals, Inc.

Phase 2 Completed
160 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡